According to Goldstein Research, global dengue vaccine market is expected to reach USD 1.15 by 2024 from USD 0.22 billion in 2016, growing at a CAGR of 17.0% over the forecast period 2016-2024. The major driving factors of the market are increasing dengue fever occurrence, local production of dengue vaccines, promising end-stage vaccine pipeline and innovation of live attenuated tetravalent dengue vaccine. Dengue vaccine industry segmentation has been carried out on the basis of technology and end user. Government Institute’s segment dominated the market and accounted for 45% market share in 2017 and a 52% market share by 2024, followed by hospitals, diagnostic labs and NGO’s. Global dengue vaccine market is largely contributed by Brazil and Mexico, estimated to be around USD 0.08 billion in 2016 and grow at a compound annual growth rate (CAGR) of 40%, followed by India, Singapore and Thailand. Market Segmentation On the basis of our in-depth analysis, Global Dengue Vaccine Mar...